cis-Dichlorodiammineplatinum(II) and adriamycin treatment of advanced ovarian cancer.
Treatment with a combination of adriamycin (ADM) and cis-dichlorodiammineplatinum(II) (DDP) has been evaluated in 24 patients with advanced ovarian cancer. Twenty patients had received prior chemotherapy and/or radiation therapy. Objective remissions were seen in ten patients. The usual toxic manifestations of ADM and DDP were observed. It is concluded that the combination is effective therapy for ovarian cancer. Further investigation of this combination versus single agents is warranted.
D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013921:Thrombocytopenia / Q000139:chemically induced
D004317:Doxorubicin; D002945:Cisplatin